Clinical Outcomes for Nasopharyngeal Cancer in Non-Asian Patients: A Single-Center Experience

Overview

Journal J Clin Med

Specialty General Medicine

Date 2025 Feb 26

PMID 40004708

Authors

Renata Zahu

Daniela Urian

Vlad Manolescu

Andrei Ungureanu

Carmen Bodale

Alexandru Iacob

Stefan Cristian Vesa

Cristina Tiple

Gabriel Kacso

Affiliations

Soon will be listed here.

Abstract

: According to Globocan, Romania has the highest incidence of nasopharyngeal cancer (NPC) in Europe. Our objective was to evaluate the survival data for a cohort of non-Asian patient population treated with curative intent at a tertiary cancer center in Romania. : We retrospectively analyzed 161 patients with histologically proven, non-metastatic NPC treated at our institution between October 2014 and December 2021 with intensity modulated arc radiotherapy (IMRT) with or without neoadjuvant or concomitant chemotherapy according to the stage of the disease. Kaplan-Meier estimates of overall, disease-free, locoregional relapse free and distant metastasis free survival were calculated. The log-rank test was used to determine significant prognostic determinants of overall and disease-free survival. : The median age was 50 years (range 19-80), 88% had nonkeratinizing undifferentiated carcinoma. Epstein Barr virus status was not evaluated routinely. 42.2% of patients were stage III and 46% stage IVA disease. Induction chemotherapy was prescribed for 72.7% of patients and 89.4% received concurrent chemotherapy. After a median follow up of 44 months (range: 3.6, 104.7 months), the estimated 3 years overall, disease free, locoregional relapse free and distant metastasis free survival of the entire cohort were 82.6%, 73.3%, 83.2% and 86.3% respectively. On testing interactions, concomitant chemotherapy offered significant survival benefit (HR-0.287; 95% CI 0.137-0.603; = 0.001) and cumulative Cisplatin dose of more than 100 mg/mp was statistically significant for survival (HR-0.350;95% CI 0.157-0.779; = 0.01) : This is the largest retrospective series of nasopharyngeal cancer from Romania reporting survival data. Despite the high percentage of advanced stage disease our data shows very good disease control. Compliance to optimal concomitant chemotherapy should represent a priority in clinical practice in a non-Asian patient population.

References

Lee A, Lee V, Ng W, Strojan P, Saba N, Rinaldo A . A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma. Eur J Cancer. 2021; 153:109-122. DOI: 10.1016/j.ejca.2021.05.022. View

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

Ribassin-Majed L, Marguet S, Lee A, Ng W, Ma J, Chan A . What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis. J Clin Oncol. 2016; 35(5):498-505. PMC: 5791836. DOI: 10.1200/JCO.2016.67.4119. View

Chan A, Hui E, Ngan R, Tung S, Cheng A, Ng W . Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial. J Clin Oncol. 2018; :JCO2018777847. DOI: 10.1200/JCO.2018.77.7847. View

Au K, Ngan R, Ng A, Poon D, Ng W, Yuen K . Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study). Oral Oncol. 2018; 77:16-21. DOI: 10.1016/j.oraloncology.2017.12.004. View

Song Y, Cheng W, Li H, Liu X . The global, regional, national burden of nasopharyngeal cancer and its attributable risk factors (1990-2019) and predictions to 2035. Cancer Med. 2022; 11(22):4310-4320. PMC: 9678109. DOI: 10.1002/cam4.4783. View

Ruuskanen M, Irjala H, Minn H, Vahlberg T, Randen-Brady R, Hagstrom J . Epstein-Barr virus and human papillomaviruses as favorable prognostic factors in nasopharyngeal carcinoma: A nationwide study in Finland. Head Neck. 2018; 41(2):349-357. PMC: 6590344. DOI: 10.1002/hed.25450. View

Bossi P, Trama A, Bernasconi A, Grisanti S, Mohamad I, Galiana I . Nasopharyngeal cancer in non-endemic areas: Impact of treatment intensity within a large retrospective multicentre cohort. Eur J Cancer. 2021; 159:194-204. DOI: 10.1016/j.ejca.2021.09.005. View

Petit C, Lee A, Ma J, Lacas B, Ng W, Chan A . Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis. Lancet Oncol. 2023; 24(6):611-623. DOI: 10.1016/S1470-2045(23)00163-8. View

10.

Zhang B, Mo Z, Du W, Wang Y, Liu L, Wei Y . Intensity-modulated radiation therapy versus 2D-RT or 3D-CRT for the treatment of nasopharyngeal carcinoma: A systematic review and meta-analysis. Oral Oncol. 2015; 51(11):1041-1046. DOI: 10.1016/j.oraloncology.2015.08.005. View

11.

Zhang Y, Rumgay H, Li M, Cao S, Chen W . Nasopharyngeal Cancer Incidence and Mortality in 185 Countries in 2020 and the Projected Burden in 2040: Population-Based Global Epidemiological Profiling. JMIR Public Health Surveill. 2023; 9:e49968. PMC: 10551785. DOI: 10.2196/49968. View

12.

Yildirim H, Kupik G, Mustafayev T, Berber T, Yavuz B, Cetinayak O . A multicenter retrospective analysis of patients with nasopharyngeal carcinoma treated in IMRT era from a nonendemic population: Turkish Society for Radiation Oncology Head and Neck Cancer Group Study (TROD 01-001). Head Neck. 2023; 45(5):1194-1205. DOI: 10.1002/hed.27333. View

13.

Wotman M, Oh E, Ahn S, Kraus D, Costantino P, Tham T . HPV status in patients with nasopharyngeal carcinoma in the United States: A SEER database study. Am J Otolaryngol. 2019; 40(5):705-710. DOI: 10.1016/j.amjoto.2019.06.007. View

14.

Fountzilas G, Ciuleanu E, Bobos M, Kalogera-Fountzila A, Eleftheraki A, Karayannopoulou G . Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology.... Ann Oncol. 2011; 23(2):427-35. DOI: 10.1093/annonc/mdr116. View

15.

Lee N, Xia P, Quivey J, Sultanem K, Poon I, Akazawa C . Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys. 2002; 53(1):12-22. DOI: 10.1016/s0360-3016(02)02724-4. View

16.

Lenoci D, Resteghini C, Serafini M, Pistore F, Canevari S, Ma B . Tumor molecular landscape of Epstein-Barr virus (EBV) related nasopharyngeal carcinoma in EBV-endemic and non-endemic areas: Implications for improving treatment modalities. Transl Res. 2023; 265:1-16. DOI: 10.1016/j.trsl.2023.10.004. View

17.

Zhang Y, Sun Y, Ma J . Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma. Cancer Commun (Lond). 2019; 39(1):39. PMC: 6593505. DOI: 10.1186/s40880-019-0385-5. View

18.

Chang E, Ye W, Zeng Y, Adami H . The Evolving Epidemiology of Nasopharyngeal Carcinoma. Cancer Epidemiol Biomarkers Prev. 2021; 30(6):1035-1047. DOI: 10.1158/1055-9965.EPI-20-1702. View

19.

Li X, Fasano R, Wang E, Yao K, Marincola F . HLA associations with nasopharyngeal carcinoma. Curr Mol Med. 2009; 9(6):751-65. PMC: 3407690. DOI: 10.2174/156652409788970698. View

20.

Zhang Y, Chen L, Hu G, Zhang N, Zhu X, Yang K . Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. N Engl J Med. 2019; 381(12):1124-1135. DOI: 10.1056/NEJMoa1905287. View